Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults wit…
Biotechnology
US, Philadelphia [HQ]
FOLD/Financials
Wall Street · Earnings · Institutional Sentiment
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Amicus Therapeutics, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | -1.2000 | -1.400 | 0 | 5 | -132 | -413 | -123 | -3 | -126 | -3 | 47 | 3 |
| 2017 | -1.4900 | -1.599 | 4 | 35 | -200 | -235 | -175 | -350 | -175 | -362 | 71 | 25 |
| 2018 | -1.8500 | -1.741 | 36 | 89 | -284 | -328 | -197 | -305 | -210 | -312 | 88 | 62 |
| 2019 | -1.8800 | -1.380 | 91 | 179 | -348 | -407 | -316 | -117 | -325 | -120 | 127 | 125 |
| 2020 | -1.4800 | -1.021 | 182 | 261 | -356 | -301 | -328 | -171 | -300 | -175 | 169 | 182 |
| 2021 | -1.0700 | -0.782 | 260 | 307 | -276 | -213 | -232 | -171 | -243 | -174 | 156 | 167 |
| 2022 | -0.9200 | -0.775 | 305 | 327 | -250 | -244 | -196 | -204 | -199 | -219 | 192 | 191 |
| 2023 | -0.8200 | -0.450 | 329 | 398 | -236 | -119 | -191 | -232 | -204 | -249 | 213 | 217 |
| 2024 | -0.5100 | -0.185 | 399 | 517 | -151 | -54 | -65 | -339 | -73 | -348 | 275 | 361 |
| 2025 | - | 0.178 | - | 640 | - | 54 | - | -420 | - | -431 | - | 448 |
| 2026 | - | 0.593 | - | 817 | - | 2.F10X | - | 2.F101 | - | 2.F1011 | - | 2.F1011 |
| 2027 | - | 1.017 | - | 985 | - | 1.F11X | - | 1.F111 | - | 1.F1111 | - | 1.F1111 |
| 2028 | - | 1.460 | - | 1,175 | - | 0.F12X | - | 0.F121 | - | 0.F1211 | - | 0.F1211 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Equal-Weight
Prev. Grade
Equal-Weight
Nov. 6, 2024
Equal-Weight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
n/a
Overall Consensus
Grading Consensus
Price Target Consensus
-80.269% $7.77 · MISS
Nov. 6, 2024Price Then
$11.74
Price Target
$17.45
Price Now
$9.68